Silver sulfadiazine 10 MG/ML Topical Cream — RxCUI 106351
RxNorm drug concept · Semantic clinical drug
RxCUI 106351
Semantic clinical drug · SCD
● Current RxNorm concept 24 FDA products
53 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI106351
Official nameSilver sulfadiazine 10 MG/ML Topical Cream
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assilver sulfadiazine 1 % Topical Cream
FDA products mapped24
Package NDCs mapped53
Reported Medicaid activity (SDUD)202,248 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Silver Sulfadiazine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Silver sulfadiazine cream is applied to second- and third-degree burn wounds to help prevent and treat serious infection. It's not a standalone treatment — your care team uses it a...
- After the wound is cleaned and any dead tissue is removed, the cream is spread in a thin layer — about 1/16 of an inch — directly over the burn area. It's applied once or twice a d...
- A temporary dip in white blood cells, especially a type called neutrophils, is actually one of the more commonly reported effects — it happens in roughly 1 in 5 patients. The good...
- My white blood cell count went down — should I be worried?
🕸️ Concept Web — How Silver sulfadiazine 10 MG/ML Topical Cream Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Silver sulfadiazine 10 MG/ML Topical Cream
RxCUI 106351 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Silver sulfadiazine
9793IN
-
Silver sulfadiazine
-
Brand names 3
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Silvadene
224926BN -
SSD
219770BN -
Thermazene
220297BN
-
Silvadene
-
Dose forms 10
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Silver sulfadiazine Topical Cream
377813SCDF -
Silver sulfadiazine Topical Product
1158745SCDG -
Silver sulfadiazine Topical Cream [Silvadene]
362123SBDF -
Silver sulfadiazine Topical Cream [SSD]
362124SBDF -
Silver sulfadiazine Topical Cream [Thermazene]
362122SBDF -
Silvadene Topical Product
1182619SBDG -
SSD Topical Product
1184188SBDG -
Thermazene Topical Product
1177356SBDG - +2 more in this family
-
Silver sulfadiazine Topical Cream
-
Clinical & branded drugs 7
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Silver sulfadiazine 10 MG/ML
343131SCDC -
Silver sulfadiazine 10 MG/ML Topical Cream [Silvadene]
208186SBD -
Silver sulfadiazine 10 MG/ML Topical Cream [SSD]
208185SBD -
Silver sulfadiazine 10 MG/ML Topical Cream [Thermazene]
208187SBD -
Silver sulfadiazine 10 MG/ML [Silvadene]
568907SBDC -
Silver sulfadiazine 10 MG/ML [SSD]
568906SBDC -
Silver sulfadiazine 10 MG/ML [Thermazene]
568908SBDC
-
Silver sulfadiazine 10 MG/ML
Showing up to 8 concepts per family — 19 of 21 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Silver sulfadiazine 10 MG/ML
SCDC · 343131 -
Silver sulfadiazine Topical Cream
SCDF · 377813 -
Silver sulfadiazine Topical Product
SCDG · 1158745
Brand-Name Concepts
-
Silver sulfadiazine 10 MG/ML Topical Cream [Silvadene]
SBD · 208186 -
Silver sulfadiazine 10 MG/ML Topical Cream [SSD]
SBD · 208185 -
Silver sulfadiazine 10 MG/ML Topical Cream [Thermazene]
SBD · 208187 -
Silver sulfadiazine 10 MG/ML [Silvadene]
SBDC · 568907 -
Silver sulfadiazine 10 MG/ML [SSD]
SBDC · 568906 -
Silver sulfadiazine 10 MG/ML [Thermazene]
SBDC · 568908 -
Silver sulfadiazine Topical Cream [Silvadene]
SBDF · 362123 -
Silver sulfadiazine Topical Cream [SSD]
SBDF · 362124 -
Silver sulfadiazine Topical Cream [Thermazene]
SBDF · 362122 -
Silvadene Topical Product
SBDG · 1182619
📦 FDA Products & Package NDCs
24 products · 53 package NDCs
53 package NDCs map to RxCUI 106351 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 87063-0078-40 | 400 g in 1 JAR (87063-078-40) | Silver Sulfadiazine | Asclemed USA, Inc. | 2026-01-23 |
| 87063-0078-50 | 50 g in 1 JAR (87063-078-50) | Silver Sulfadiazine | Asclemed USA, Inc. | 2026-01-23 |
| 87063-0078-85 | 85 g in 1 TUBE (87063-078-85) | Silver Sulfadiazine | Asclemed USA, Inc. | 2026-01-23 |
Observed labelers:
Asclemed USA, Inc. (9) ·
Ascend Laboratories, LLC (7) ·
Pfizer Laboratories Div Pfizer Inc (7) ·
A-S Medication Solutions (6) ·
Bryant Ranch Prepack (6) ·
Mylan Pharmaceuticals Inc. (6)
· +7 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.